Lavomax [Tilorone]


Active ingredient: tilorone dihydrochloride 125 mg.

Inactive ingredients: magnesium hydroxycarbonate, povidone K30 and calcium stearate


1 tablet per day during the first 2 days, then 1 tablet once every 2 days.

To be administered orally after meal.

Maximum dose for influenza and ARVI treatment course is 750 mg (6 tablets).

Maximum dose for herpes and other viral infections treatment course is 1.25ÔÇô2.5 mg (10ÔÇô20 tablets).

Side effects

Allergic response, dyspepsia and short-term chills.


No cases of overdose were recorded.

Drug interaction

The drug can be co-administered with antibiotics and medicines treating viral and bacterial diseases. No significant drug interactions were recorded.

Storage conditions

Store in a dark place at a temperature not higher than 25┬░C (77┬░F). Keep out of the reach of children.

Shelf life is 2 years.

Lavomax is an immunomodulating and antiviral drug intended for treatment and prevention of respiratory and other viral diseases.

Tilorone, its active ingredient, stimulates the production of interferons (proteins essential for anti-viral defence) and enhances the immunity during influenza and ARVI. The synthesis method and antiviral properties of tilorone were first patented in 1968 in the USA. In USSR the production and use of this drug started in 1975.

Research demonstrated that Lavomax is effective in treating viral infections, including influenza and other acute respiratory viral infections, hepatitis and herpes, cytomegalovirus and neurotropic viruses. The drug inhibits viral translation in the infected cells and prevents the spread of viruses, thus showing a strong antiviral effect.

Pharmacodynamic properties

Lavomax stimulates the production of alpha, beta, and gamma types of interferons in intestinal epithelial cells, hepatocytes, T-cells and neutrophils.

It also contributes to the growth of bone marrow cells and enhances antibody production, stabilizes the level of immunosuppression and regulates the T-Lymphocyte Helper/Suppressor ratio.


As part of complex therapy of:

  • influenza and ARVI;
  • herpes.
  • Prevention of influenza and ARVI.
  • The drug can also be used as part of complex therapy of viral hepatitis A, B and C, cytomegalovirus infection and non-gonococcal urethritis.
  • Counterindications

    Hypersensitivity to tilorone and other components of the drug.

    Pregnancy and lactation.

    Children under 18 years of age.

    Sucrase-isomaltase deficiency, fructose intolerance or glucose-galactose malabsorption (the drug contains sucrose).

    1. Glaz et al (1973) Antiviral Activity and Induction of Interferon-Like Substance by Quinacrine and Acranil
    2. Levine et al (1975) Nuclear bodies produced in astrocytes by tilorone
    3. Kuehne et al (1977) Evaluation of Various Analogues of Tilorone Hydrochloride Against Venezuelan Equine Encephalitis Virus in Mice
    4. Donahoe et al (1977) In vivo function tests of the effect of tilorone and niridazole on cell-mediated immunity in chickens
    5. Kavetski─ş et al (1977) Tilorone, a synthetic immunostimulator possessing antitumor activity
    6. Cummings et al (1981) Phase II trials of Baker's antifol, bleomycin, CCNU, streptozotocin, tilorone, and 5-fluorodeoxyuridine plus arabinosyl cytosine in metastatic breast cancer
    7. Y Hiyama, K Kuriyama et al (1991) Dissociation between antiinflammatory action of tilorone and its interferon inducing activity
    8. Selkova et al (2001) Effect of amyxin--a domestic analog of tilorone--on characteristics of interferon and immune status of man
    9. Briggs et al (2008) ╬▒7 nicotinic acetylcholine receptor agonist properties of tilorone and related tricyclic analogues
    10. Ratan et al (2010) Small Molecule Activation of Adaptive Gene Expression. Tilorone or Its Analogs Are Novel Potent Activators of Hypoxia Inducible Factor-1 That Provide Prophylaxis against Stroke and Spinal Cord Injury
    11. Schrimpf et al (2012) SAR of ╬▒7 nicotinic receptor agonists derived from tilorone: exploration of a novel nicotinic pharmacophore
    12. Lepp├Ąranta et al (2013) Bone morphogenetic protein-inducer tilorone identified by high-throughput screening is antifibrotic in vivo
    13. Wissing et al (2014) Small-molecule screening of PC3 prostate cancer cells identifies tilorone dihydrochloride to selectively inhibit cell growth based on cyclin-dependent kinase 5 expression
    14. Ekins et al (2018) Efficacy of Tilorone Dihydrochloride against Ebola Virus Infection
    15. Vartiainen et al (2018) Pulmonary administration of a dry powder formulation of the antifibrotic drug tilorone reduces silica-induced lung fibrosis in mice

    Type: Unknown Type